Cantor Fitzgerald Analysts Give Intercept Pharmaceuticals (ICPT) a $58.00 Price Target

Intercept Pharmaceuticals (NASDAQ:ICPT) has been assigned a $58.00 target price by equities researchers at Cantor Fitzgerald in a note issued to investors on Wednesday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 8.59% from the stock’s previous close.

Several other equities research analysts have also recently commented on the company. Wedbush reaffirmed a “buy” rating and set a $253.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, January 5th. Deutsche Bank initiated coverage on Intercept Pharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $106.00 price objective on the stock. Goldman Sachs Group cut Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a research report on Wednesday, February 7th. Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, Laidlaw raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Wednesday, November 1st. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $132.38.

Intercept Pharmaceuticals (NASDAQ ICPT) traded down $1.22 during trading on Wednesday, hitting $53.41. The company had a trading volume of 768,900 shares, compared to its average volume of 1,085,380. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. Intercept Pharmaceuticals has a 12 month low of $51.05 and a 12 month high of $135.59. The stock has a market capitalization of $1,340.00, a PE ratio of -3.52 and a beta of -2.13.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The business had revenue of $37.69 million for the quarter, compared to analysts’ expectations of $39.01 million. During the same period last year, the business earned ($4.84) earnings per share. The company’s quarterly revenue was up 173.1% on a year-over-year basis. research analysts anticipate that Intercept Pharmaceuticals will post -13.52 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Altrinsic Global Advisors LLC increased its stake in Intercept Pharmaceuticals by 33.4% in the 4th quarter. Altrinsic Global Advisors LLC now owns 310,300 shares of the biopharmaceutical company’s stock worth $18,128,000 after acquiring an additional 77,756 shares during the last quarter. Amalgamated Bank bought a new stake in Intercept Pharmaceuticals in the 4th quarter worth approximately $209,000. Hudson Bay Capital Management LP bought a new stake in Intercept Pharmaceuticals in the 4th quarter worth approximately $1,753,000. Senvest Management LLC increased its stake in Intercept Pharmaceuticals by 66.3% in the 4th quarter. Senvest Management LLC now owns 970,926 shares of the biopharmaceutical company’s stock worth $56,721,000 after acquiring an additional 387,136 shares during the last quarter. Finally, Spark Investment Management LLC increased its stake in Intercept Pharmaceuticals by 43.9% in the 4th quarter. Spark Investment Management LLC now owns 181,110 shares of the biopharmaceutical company’s stock worth $10,580,000 after acquiring an additional 55,210 shares during the last quarter. 75.48% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/14/cantor-fitzgerald-analysts-give-intercept-pharmaceuticals-icpt-a-58-00-price-target.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply